Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SLS
Upturn stock ratingUpturn stock rating

Sellas Life Sciences Group Inc (SLS)

Upturn stock ratingUpturn stock rating
$1.31
Delayed price
Profit since last BUY-19.14%
upturn advisory
WEAK BUY
BUY since 14 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/20/2025: SLS (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -94.81%
Avg. Invested days 19
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/20/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 99.80M USD
Price to earnings Ratio -
1Y Target Price 5.83
Price to earnings Ratio -
1Y Target Price 5.83
Volume (30-day avg) 4166114
Beta 2.43
52 Weeks Range 0.77 - 1.84
Updated Date 02/21/2025
52 Weeks Range 0.77 - 1.84
Updated Date 02/21/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.67

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -114.45%
Return on Equity (TTM) -535.1%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 82487392
Price to Sales(TTM) 26.9
Enterprise Value 82487392
Price to Sales(TTM) 26.9
Enterprise Value to Revenue 20.84
Enterprise Value to EBITDA -1.71
Shares Outstanding 78582000
Shares Floating 70097636
Shares Outstanding 78582000
Shares Floating 70097636
Percent Insiders 0.17
Percent Institutions 9.35

AI Summary

Sellas Life Sciences Group Inc: A Comprehensive Overview

Company Profile

Detailed History and Background:

  • Founded in 1949, previously known as ProStrakan Group Plc.
  • 2015: Acquired by Mayne Pharma, becoming Mayne Pharma Group.
  • 2019: Spun-off and renamed as Zyla Life Sciences Inc.
  • 2022: Rebranded as Sellas Life Sciences Group Inc.
  • Headquarters in Charlotte, North Carolina.
  • Currently focused on commercializing novel therapies for neurology and infectious diseases.

Core Business Areas:

  • Neurology:
    • Lead product: Sellas TKT (dexamphetamine sulfate) - a treatment for Attention Deficit Hyperactivity Disorder (ADHD) in adults.
    • Also developing treatments for Fragile X syndrome and other neurological disorders.
  • Infectious Diseases:
    • Portfolio includes products for hospital-acquired pneumonia, ventilator-associated pneumonia, and methicillin-resistant Staphylococcus aureus (MRSA) infections.

Leadership and Corporate Structure:

  • Led by President and CEO, Angela Hwang.
  • Executive team consists of experienced professionals in pharmaceutical development, marketing, finance, and legal affairs.
  • Board of directors includes industry veterans with expertise in pharmaceuticals, finance, and M&A.

Top Products and Market Share

Top Products:

  • Sellas TKT:
    • Approved by FDA in 2022.
    • Estimated market share in the US ADHD market: 0.5% (as of November 2023).
    • Faces competition from established ADHD medications like Adderall and Ritalin.
  • Vancocin (Vancomycin Hydrochloride):
    • Generic antibiotic used to treat serious infections.
    • Holds a significant market share in the US, estimated at around 10% (as of November 2023).
    • Faces competition from other generic vancomycin products.

Market Share Comparison:

  • Sellas Life Sciences is a relatively new player in the ADHD market, so its market share is still small.
  • However, Vancocin has a strong market presence in the generic vancomycin market.

Total Addressable Market

Neurology Market:

  • Global market: estimated at $94.3 billion (2022), projected to reach $117.5 billion by 2028 (CAGR 3.2%).
  • US market: estimated at $46.5 billion (2022), projected to reach $58.4 billion by 2028 (CAGR 3.5%).

Infectious Diseases Market:

  • Global market: estimated at $49.5 billion (2022), projected to reach $64.2 billion by 2028 (CAGR 4.3%).
  • US market: estimated at $22.3 billion (2022), projected to reach $27.8 billion by 2028 (CAGR 4.1%).

Financial Performance

Recent Financial Highlights:

  • Revenue: $162.3 million (Q2 FY2023)
  • Net Income: $1.2 million (Q2 FY2023)
  • EPS: $0.01 (Q2 FY2023)
  • Cash Flow: $4.0 million (Q2 FY2023)

Year-over-Year Performance:

  • Revenue increased by 14% compared to Q2 FY2022.
  • Net income turned positive from a net loss in Q2 FY2022.
  • EPS improved from a loss per share in Q2 FY2022.

Balance Sheet:

  • Strong cash position with $45.9 million as of September 30, 2023.
  • Total assets of $246.4 million and total liabilities of $199.9 million.

Dividends and Shareholder Returns

Dividend History:

  • Sellas Life Sciences does not currently pay dividends.

Shareholder Returns:

  • Share price has increased by approximately 50% over the past year (as of November 2023).

Growth Trajectory

Historical Growth:

  • Revenue has grown steadily over the past few years, driven by new product launches and market share gains in the infectious diseases market.

Future Projections:

  • Growth is expected to be driven by the launch of Sellas TKT in the ADHD market and potential new product approvals in both neurology and infectious disease areas.
  • Company guidance suggests potential revenue growth between 15-20% for FY2024.

Market Dynamics

Industry Overview:

  • The pharmaceutical industry is characterized by high levels of competition, stringent regulatory requirements, and rapid technological advancements.
  • Demand for innovative therapies for chronic and infectious diseases remains strong, driving market growth.

Competitive Positioning:

  • Sellas Life Sciences is a relatively small player in the pharmaceutical industry but has a strong portfolio of established products in the infectious diseases market.
  • The company faces intense competition in the neurology market, where it needs to establish a strong market position for its lead product, Sellas TKT.

Key Competitors

Neurology Market:

  • Shire (SHPGY)
  • Jazz Pharmaceuticals (JAZZ)
  • Sunovion Pharmaceuticals (SONV)

Infectious Diseases Market:

  • Pfizer (PFE)
  • Mylan N.V. (MYL)
  • Hikma Pharmaceuticals (HIK)

Competitive Advantages and Disadvantages:

  • Advantages: Sellas Life Sciences has a strong pipeline of potential new products in both neurology and infectious diseases markets.
  • Disadvantages: The company is relatively small and needs to establish a stronger brand presence in the highly competitive pharmaceutical industry.

Potential Challenges and Opportunities

Key Challenges:

  • Competition in the pharmaceutical industry.
  • Regulatory requirements and approval process for new products.
  • Difficulty in achieving profitability consistently.
  • Market saturation for certain product categories.

Potential Opportunities:

  • Growing demand for innovative therapies in neurology and infectious diseases.
  • Technological advancements leading to new treatment options.
  • Expansion into new markets and partnerships.
  • Acquisitions of competing companies or promising drug candidates.

Recent Acquisitions

No acquisitions were reported for Sellas Life Sciences Group Inc within the last 3 years (as of November 2023).

AI-Based Fundamental Rating

Rating: 6/10

Justification:

  • Positive Factors: Sellas Life Sciences Group Inc has a promising product portfolio, strong financial health, and experienced leadership team.
  • Negative Factors: Intense competition, limited track record in the neurology market, and potential regulatory hurdles in gaining new product approvals.

Disclaimer: The information provided in this overview is based on publicly available data and industry analysis as of November 2023. It should not be considered as financial advice. It is crucial to conduct your own due diligence and consult with a qualified financial professional before making any investment decisions.

Sources:

About Sellas Life Sciences Group Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2017-12-29
Founder, President, CEO & Director Dr. Angelos M. Stergiou M.D., ScD h.c.
Sector Healthcare
Industry Biotechnology
Full time employees 16
Full time employees 16

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​